Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review

INTRODUCTION: Pembrolizumab, an immune checkpoint inhibitor for treating non-small cell lung cancer (NSCLC), can impose a high financial burden. Several studies have explored the cost-effectiveness of this expensive agent. We conducted a systematic review and pooled analysis to evaluate the quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chuan, Zhang, Jiaxu, Tan, Jing, Tian, Panwen, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469648/
https://www.ncbi.nlm.nih.gov/pubmed/36110966
http://dx.doi.org/10.3389/fonc.2022.815587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469648/
https://www.ncbi.nlm.nih.gov/pubmed/36110966
http://dx.doi.org/10.3389/fonc.2022.815587

Ejemplares similares